AstraZeneca Targets $80 Billion Revenue by 2030 with 20 New Medicines

The pharmaceutical giant aims to nearly double its revenue through a strong focus on oncology, biopharmaceuticals, and rare diseases.

AstraZeneca plans to launch 20 new drugs to achieve its ambitious revenue goal.
The company aims to leverage its oncology and rare disease portfolios for significant growth.
Investment in advanced technologies like antibody-drug conjugates and radiopharmaceuticals is a key strategy.
AstraZeneca has ceased production of its COVID-19 vaccine due to reduced demand.
A new $1.5 billion manufacturing facility in Singapore will support the production of innovative cancer treatments.